U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07417124) titled 'Assess the Safety and Tolerability of SNS851 in Healthy Participants' on Jan. 22.
Brief Summary: This is a Phase I, randomized, double-blind study designed to evaluate the safety, tolerability and pharmacokinetics of subcutaneous administration of SNS851 in healthy participants.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Metabolic Disease
Intervention:
DRUG: SNS851
SNS851 is a potent siRNA treatment targeting metabolic diseases.
OTHER: Placebo
Normal saline
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Oneness Biotech Co., Ltd.
Published by HT Digital Content Services with permission from Healt...